Key result
Down-regulation of Prkar1a by up to 70% in transgenic mice led to thyroid follicular hyperplasia, adenomas, adrenocortical hyperplasia, and other mesenchymal tumors.
Why the study?
Does down-regulation of Prkar1a lead to tumorigenesis in endocrine and other tissues in a transgenic mouse model?
Does down-regulation of Prkar1a lead to tumorigenesis in endocrine and other tissues in a transgenic mouse model?
The establishment of a novel transgenic mouse model confirms the critical role of Prkar1a down-regulation in the tumorigenesis of endocrine and other tissues.
Answers are grounded in this paper and cite their sources.
Prkar1a down-regulation is associated with tumors in mice; leaves open human relevance and should not change practice.
Mutations of the human type Ialpha regulatory subunit (RIalpha) of cyclic AMP-dependent protein kinase (PKA; PRKAR1A) lead to altered kinase activity, primary pigmented nodular adrenocortical disease, and tumors of the thyroid and other tissues. To bypass the early embryonic lethality of Prkar1a(-/-) mice, we established transgenic mice carrying an antisense transgene for Prkar1a exon 2 (X2AS) under the control of a tetracycline-responsive promoter. Down-regulation of Prkar1a by up to 70% was achieved in transgenic mouse tissues and embryonic fibroblasts, with concomitant changes in kinase activity and increased cell proliferation, respectively. Mice developed thyroid follicular hyperplasia and adenomas, adrenocortical hyperplasia, and other features reminiscent of primary pigmented nodular adrenocortical disease, histiocytic and epithelial hyperplasias, lymphomas, and other mesenchymal tumors. These were associated with allelic losses of the mouse chromosome 11 Prkar1a locus, an increase in total type II PKA activity, and higher RIIbeta protein levels. This mouse provides a novel, useful tool for the investigation of cyclic AMP, RIalpha, and PKA functions and confirms the critical role of Prkar1a in tumorigenesis in endocrine and other tissues.
No takes yet. Share an insight, caveat, or question.
Griffin et al. (2004) studied Endocrine and other tumors. Down-regulation of Prkar1a via antisense transgene (X2AS) was evaluated on Tumor development (thyroid follicular hyperplasia, adenomas, adrenocortical hyperplasia, and other tumors). Down-regulation of Prkar1a by up to 70% in transgenic mice led to thyroid follicular hyperplasia, adenomas, adrenocortical hyperplasia, and other mesenchymal tumors.
Synapse has enriched 10 related papers. Consider them for comparative context: